Company news: Amgen and DeCODE Genetics; Porter Novelli

Share this article:
Amgen is buying deCODE Genetics, an Icelandic firm, for $415 million in cash. DeCODE Genetics' work has focused on identifying genetic risk factors for diseases ranging from cardiovascular disease to cancer. “This capability will enhance our efforts to identify and validate human disease targets,” said Robert A. Bradway, president and CEO of Amgen. “This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programs based on less well-validated targets.”

Porter Novelli named Paul George director of health. George, who joins from Omnicom healthcare communications agency TogoRun, where he was SVP and partner, starts Jan. 1. In that most recent role, George led global integrated marketing communications programs for clients including BMS and Gilead. He also served as the lead for TogoHealth in an Omnicom initiative to identify and pitch new healthcare business across agencies. Porter Novelli New York senior partner and managing director Karen van Bergen said of George: “As more and more clients look to holding companies to create multi-agency marketing partnerships, Paul's experience will be invaluable as we build the cross-border, cross-discipline solutions that clients need to grow their businesses.”
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.